Literature DB >> 9179711

Radiographic examination of the small bowel. An application of odds ratio analysis to help attain an appropriate mix of small bowel follow through and enteroclysis in a working-clinical environment.

G N Bender1.   

Abstract

RATIONALE AND
OBJECTIVES: Simplifying data collection and analysis should promote utilization management in review of examinations of the small bowel in the general practice.
METHODS: A case control format with the generation of an odds ratio to answer sets of binary questions derived from annual examination data is shown. The positive examination results applied were compared with the literature as a cross-checking mechanism. The examination identified as most likely to be positive was recommended prospectively in a protocol for the following year. Two of 5 years are illustrated to emphasize the development of the methodology.
RESULTS: Application of this model in testing its validity, since 1990 at Madigan Army Medical Center, allows for the generation of a new protocol each year to prospectively improve clinical definition.
CONCLUSIONS: A 5-year analysis of small bowel examination protocols, subdivisions, and odds ratios, will be forthcoming. The 2 years illustrated show how strongly our practice was influenced in using enteroclysis or in using the small bowel follow through as the examination of choice in the various clinical categories of small bowel disease: (1) practice was influenced by protocol and (2) outcome was steered toward positive examinations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179711     DOI: 10.1097/00004424-199706000-00007

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  1 in total

1.  Multi-detector CT enterography with iso-osmotic mannitol as oral contrast for detecting small bowel disease.

Authors:  Lian-He Zhang; Shi-Zheng Zhang; Hong-Jie Hu; Min Gao; Ming Zhang; Qian Cao; Qiao-Wei Zhang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.